The main outcome measurements included logMAR visual acuity and central foveal thickness (CFT) before surgery and at 3, 6, 9, and 12Â months after vitrectomy. This study was designed as a prospective, randomized, multicenter study comparing 19 eyes of 19 patients who received 150 units of kallidinogenase administered a day for 52Â weeks from the day after vitrectomy (study group) with 20 eyes of 20 patients who received no kallidinogenase (control group).
To evaluate the effectiveness of the combination of vitrectomy with kallidinogenase for diabetic macular edema (DME). Yoshizumi, Yuki Ohara, Zaigen Tabuchi, Hitoshi Sumino, Hitomi Maeda, Yukiko Mochizuki, Hideki Yamane, Ken Kiuchi, Yoshiaki
Effects of kallidinogenase in patients undergoing vitrectomy for diabetic macular edema.
0 kommentar(er)
